A Caltech Library Service

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

Zuckerman, Jonathan E. and Davis, Mark E. (2015) Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nature Reviews Drug Discovery, 14 (12). pp. 843-856. ISSN 1474-1776. doi:10.1038/nrd4685.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


Small interfering RNA (siRNA)-based therapies are emerging as a promising new anticancer approach, and a small number of Phase I clinical trials involving patients with solid tumours have now been completed. Encouraging results from these pioneering clinical studies show that these new therapeutics can successfully and safely inhibit targeted gene products in patients with cancer, and have taught us important lessons regarding appropriate dosages and schedules. In this Review, we critically assess these Phase I studies and discuss their implications for future clinical trial design. Key challenges and future directions in the development of siRNA-containing anticancer therapeutics are also considered.

Item Type:Article
Related URLs:
URLURL TypeDescription ReadCube access
Davis, Mark E.0000-0001-8294-1477
Additional Information:© 2015 Macmillan Publishers Limited. Published online 16 November 2015. Competing interests statement: M.E.D. has stock in and is a consultant to Cerulean Pharma, Avidity NanoMedicines and Intellia Therapeutics.
Issue or Number:12
Record Number:CaltechAUTHORS:20151123-102043206
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:62323
Deposited By: Tony Diaz
Deposited On:23 Nov 2015 18:53
Last Modified:10 Nov 2021 23:00

Repository Staff Only: item control page